HDL as a drug and nucleic acid delivery vehicle
This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein=type nanoparticles. These macromolecules provide targeted transpo...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2015-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00247/full |
id |
doaj-1de9437f91444bbb927f1f250e4c6ee7 |
---|---|
record_format |
Article |
spelling |
doaj-1de9437f91444bbb927f1f250e4c6ee72020-11-24T20:56:02ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122015-10-01610.3389/fphar.2015.00247158940HDL as a drug and nucleic acid delivery vehicleAndras G Lacko0Nirupama Avinash Sabnis1Bhavani eNagarajan2Walter James McConathy3University of North Texas Health Science CenterUniversity of North Texas Health Science CenterUniversity of North Texas Health Science CenterLipoMedics IncThis review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein=type nanoparticles. These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic payload) in their natural/physiological environment. The property of accommodating highly water insoluble constituents in their core region enables HDL type nanoparticles to effectively transport hydrophobic drugs upon intravenous administration. Even though the application of reconstituted HDL in the treatment of a number of diseases is reviewed, the primary focus is on the application of HDL type drug delivery agents in cancer chemotherapy. The use of both native and synthetic HDL as drug delivery agents are compared to evaluate their respective potentials for commercial and clinical development. The current status and future perspectives for HDL type nanoparticles are discussed, including current obstacles and future applications in therapeutics.http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00247/fullHDLDrug deliverytargeting factorstumor selective therapeuticsenhanced therapeutics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Andras G Lacko Nirupama Avinash Sabnis Bhavani eNagarajan Walter James McConathy |
spellingShingle |
Andras G Lacko Nirupama Avinash Sabnis Bhavani eNagarajan Walter James McConathy HDL as a drug and nucleic acid delivery vehicle Frontiers in Pharmacology HDL Drug delivery targeting factors tumor selective therapeutics enhanced therapeutics |
author_facet |
Andras G Lacko Nirupama Avinash Sabnis Bhavani eNagarajan Walter James McConathy |
author_sort |
Andras G Lacko |
title |
HDL as a drug and nucleic acid delivery vehicle |
title_short |
HDL as a drug and nucleic acid delivery vehicle |
title_full |
HDL as a drug and nucleic acid delivery vehicle |
title_fullStr |
HDL as a drug and nucleic acid delivery vehicle |
title_full_unstemmed |
HDL as a drug and nucleic acid delivery vehicle |
title_sort |
hdl as a drug and nucleic acid delivery vehicle |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2015-10-01 |
description |
This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein=type nanoparticles. These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic payload) in their natural/physiological environment. The property of accommodating highly water insoluble constituents in their core region enables HDL type nanoparticles to effectively transport hydrophobic drugs upon intravenous administration. Even though the application of reconstituted HDL in the treatment of a number of diseases is reviewed, the primary focus is on the application of HDL type drug delivery agents in cancer chemotherapy. The use of both native and synthetic HDL as drug delivery agents are compared to evaluate their respective potentials for commercial and clinical development. The current status and future perspectives for HDL type nanoparticles are discussed, including current obstacles and future applications in therapeutics. |
topic |
HDL Drug delivery targeting factors tumor selective therapeutics enhanced therapeutics |
url |
http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00247/full |
work_keys_str_mv |
AT andrasglacko hdlasadrugandnucleicaciddeliveryvehicle AT nirupamaavinashsabnis hdlasadrugandnucleicaciddeliveryvehicle AT bhavanienagarajan hdlasadrugandnucleicaciddeliveryvehicle AT walterjamesmcconathy hdlasadrugandnucleicaciddeliveryvehicle |
_version_ |
1716791029481340928 |